KT-621, Placebo oral tablet matched to KT-621, KT-621, KT-621
KT621-AS-202
Phase 2 small_molecule active
Quick answer
KT-621, Placebo oral tablet matched to KT-621, KT-621, KT-621 for Uncontrolled Moderate to Severe Eosinophilic Asthma is a Phase 2 program (small_molecule) at Kymera Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kymera Therapeutics
- Indication
- Uncontrolled Moderate to Severe Eosinophilic Asthma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active